Bimatoprost

Generic Name: Bimatoprost

Brand Names: Durysta, Latisse, Lumigan

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₃₇NO_₄

CAS Number: 155206-00-1

Unique Ingredient Identifier: QXS94885MZ

Background: Bimatoprost, also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. It has the ability to reduce ocular hypotension, proving effective in conditions such as ocular hypertension and glaucoma. Bimatoprost is also used to treat eyelash hypotrichosis, or sparse eyelash growth. It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis in 2008, as eyelash growth became a desirable adverse effect for patients using this drug.

Indication: Bimatoprost is used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

These patients must be intolerant to other intraocular pressure lowering medications or inadequately responsive to other treatments.

Bimatoprost is also indicated to treat eyelash hypotrichosis.

Associated Conditions: Hypotrichosis of the eyelashes, Increased Intra Ocular Pressure (IOP)

Clinical Trials

Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension

Phase 2

Completed

Conditions: Glaucoma, Open-Angle
Ocular Hypertension

Interventions: Drug: AGN-210669
Drug: bimatoprost vehicle
Drug: bimatoprost

First Posted Date: 2011-02-08

Last Posted Date: 2013-11-06

Lead Sponsor: Allergan

Target Recruit Count: 125

Registration Number: NCT01291108

24-hour IOP-lowering Effect of 0.01% Bimatoprost

Phase 4

Completed

Conditions: Intraocular Pressure
Ocular Hypertension
Glaucoma

Interventions: Drug: 0.01% bimatoprost

First Posted Date: 2011-01-07

Last Posted Date: 2014-06-19

Lead Sponsor: University of California, San Diego

Target Recruit Count: 16

Registration Number: NCT01271686

Locations: 🇺🇸
UCSD Shiley Eye Center, La Jolla, California, United States

Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension

Phase 4

Completed

Conditions: Glaucoma, Open-Angle
Ocular Hypertension

Interventions: Drug: travoprost ophthalmic solution 0.004%
Drug: latanoprost ophthalmic solution 0.005%
Drug: bimatoprost ophthalmic solution 0.01%

First Posted Date: 2010-12-06

Last Posted Date: 2012-11-07

Lead Sponsor: Allergan

Target Recruit Count: 164

Registration Number: NCT01253902

Safety and Efficacy of Bimatoprost/Timolol Fixed Combination Versus Latanoprost in Patients With Open-Angle Glaucoma Who Have Never Been Treated

Phase 4

Completed

Conditions: Glaucoma, Open-Angle

Interventions: Drug: latanoprost 0.005% ophthalmic solution
Drug: bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution

First Posted Date: 2010-11-18

Last Posted Date: 2019-04-18

Lead Sponsor: Allergan

Target Recruit Count: 81

Registration Number: NCT01243567

Safety and Efficacy of LATISSE® in the Augmentation of Eyelashes of Korean Subjects

Phase 4

Completed

Conditions: Eyelash Hypotrichosis

Interventions: Drug: bimatoprost 0.03%

First Posted Date: 2010-10-27

Last Posted Date: 2019-01-29

Lead Sponsor: Allergan

Target Recruit Count: 62

Registration Number: NCT01229423

Topical Bimatoprost Solution 0.03%in Stable Vitiligo

Phase 4

Withdrawn

Conditions: Vitiligo
Repigmentation

Interventions: Drug: Bimatoprost 0.03% topical ophthalmic solution

First Posted Date: 2010-09-16

Last Posted Date: 2011-08-03

Lead Sponsor: Gian Sagar Medical College and Hospital

Target Recruit Count: 20

Registration Number: NCT01202513

Study of Bimatoprost Gel on Eyelash Growth

Phase 3

Completed

Conditions: Hypotrichosis
Madarosis

Interventions: Drug: Bimatoprost eyelash gel

First Posted Date: 2010-09-13

Last Posted Date: 2014-07-16

Lead Sponsor: Duke University

Target Recruit Count: 20

Registration Number: NCT01200251

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia

Phase 1

Completed

Conditions: Alopecia
Alopecia, Androgenetic
Baldness

Interventions: Drug: bimatoprost Formulation A
Drug: bimatoprost Formulation B
Drug: bimatoprost Formulation C

First Posted Date: 2010-08-26

Last Posted Date: 2013-08-30

Lead Sponsor: Allergan

Target Recruit Count: 42

Registration Number: NCT01189279

Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Glaucoma
Ocular Hypertension

Interventions: Drug: bimatoprost /timolol formulation A fixed combination ophthalmic solution
Drug: bimatoprost/timolol fixed combination ophthalmic solution

First Posted Date: 2010-08-06

Last Posted Date: 2013-03-29

Lead Sponsor: Allergan

Target Recruit Count: 561

Registration Number: NCT01177098

Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®

Phase 4

Completed

Conditions: Glaucoma
Ocular Hypertension

Interventions: Drug: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution
Drug: bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops

First Posted Date: 2010-07-27

Last Posted Date: 2019-04-24

Lead Sponsor: Allergan

Target Recruit Count: 121

Registration Number: NCT01170884

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy